Replimune Group, Inc.

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies to treat cancer. Its proprietary product candidates are designed to activate the immune system against tumors. The lead candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, targeting a range of solid tumors. The company is also developing RP2, which expresses an anti-CTLA-4 antibody-like protein to block immune inhibition caused by CTLA-4, and RP3, which expresses immune-activating proteins that stimulate T cells. Replimune operates in the United States and the United Kingdom.

Replimune Group, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol REPL. The company's stock trades in US dollars (USD), reflecting its primary listing in the United States.

Replimune Group, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative oncolytic immunotherapies that leverage viruses to activate the immune system against cancer cells.

Replimune Group, Inc. is headquartered in Woburn, Massachusetts, United States. The company serves markets in the United States and the United Kingdom, where it conducts its research and development activities for its oncolytic immunotherapy product candidates.

Replimune's lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, designed for a range of solid tumors. The company is also developing RP2, which expresses an anti-CTLA-4 antibody-like protein to block CTLA-4-mediated immune inhibition, and RP3, which expresses immune-activating proteins that stimulate T cells. All candidates are based on the company's proprietary oncolytic immunotherapy platform aimed at activating the immune system against cancer.